2301 Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538) in Patients with Esophageal Cancer: Preliminary Report. (September 2015) - Takashi, U.; Muro, K.; Hara, H.; Yamaguchi, K.; Hironaka, S.; Iwasa, S.; Kato, K.; Kojima, T.; Tsushima, T.; Yasui, H.; Satoh, T.; Doki, Y.; et al.